Immunovant, Roivant slip after trial data for autoimmune disorder therapy
Immunovant's (NASDAQ:IMVT) stock and Roivant Sciences (ROIV) stock fall after trial data for the former's autoimmune disease ...
Immunovant price target raised to $61 from $58 at Stifel
Stifel analyst Alex Thompson raised the firm’s price target on Immunovant (IMVT) to $61 from $58 and keeps a Buy rating on the shares following ...
Immunovant price target lowered to $33 from $38 at BofA
BofA lowered the firm’s price target on Immunovant (IMVT) to $33 from $38 and keeps a Buy rating on the shares after yesterday’s topline data ...
Immunovant claims study success for immune disease drug but holds off on submission
The company continues to focus on a next-generation drug while batoclimab’s testing in thyroid eye disease wraps up.
Fierce Biotech1d
Immunovant won't seek approval for autoimmune drug despite phase 3 win
Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data
Immunovant, Inc. (NASDAQ:IMVT) released topline results from its Phase 3 study of batoclimab in myasthenia gravis (MG) and ...
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...
BioSpace1d
Immunovant Will Drop One Myasthenia Gravis Asset, Continuing to Favor Another
Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...
STAT1d
Immunovant and Roivant report success in autoimmune drug’s Phase 3 trial
The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.
Immunovant's muscle drug meets main goal, shares gain on new drug promise
Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.
STAT7h
Zealand’s obesity strategy and Immunovant’s curious development plan
For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal with Roche, go here; and to read about the panels at our Breakthrough East ...
The Pharma Letter1d
Positive batoclimab data from Immunovant, but doubts raised on further development
Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...